Switch to:
Also traded in: Brazil, Chile, Germany, Mexico, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.54
GILD's Cash-to-Debt is ranked lower than
89% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. GILD: 0.54 )
Ranked among companies with meaningful Cash-to-Debt only.
GILD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15  Med: 1.74 Max: N/A
Current: 0.54
Equity-to-Asset 0.35
GILD's Equity-to-Asset is ranked lower than
82% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. GILD: 0.35 )
Ranked among companies with meaningful Equity-to-Asset only.
GILD' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.62 Max: 0.98
Current: 0.35
0.21
0.98
Interest Coverage 16.83
GILD's Interest Coverage is ranked lower than
81% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GILD: 16.83 )
Ranked among companies with meaningful Interest Coverage only.
GILD' s Interest Coverage Range Over the Past 10 Years
Min: 11.11  Med: 34.31 Max: 165.23
Current: 16.83
11.11
165.23
Piotroski F-Score: 5
Altman Z-Score: 3.59
Beneish M-Score: -3.04
WACC vs ROIC
7.07%
41.49%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 57.55
GILD's Operating Margin % is ranked higher than
97% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. GILD: 57.55 )
Ranked among companies with meaningful Operating Margin % only.
GILD' s Operating Margin % Range Over the Past 10 Years
Min: 40.39  Med: 50.27 Max: 68
Current: 57.55
40.39
68
Net Margin % 43.42
GILD's Net Margin % is ranked higher than
96% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. GILD: 43.42 )
Ranked among companies with meaningful Net Margin % only.
GILD' s Net Margin % Range Over the Past 10 Years
Min: 26.72  Med: 37.34 Max: 55.48
Current: 43.42
26.72
55.48
ROE % 74.22
GILD's ROE % is ranked higher than
99% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. GILD: 74.22 )
Ranked among companies with meaningful ROE % only.
GILD' s ROE % Range Over the Past 10 Years
Min: 29.75  Med: 50.37 Max: 106.64
Current: 74.22
29.75
106.64
ROA % 23.49
GILD's ROA % is ranked higher than
97% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. GILD: 23.49 )
Ranked among companies with meaningful ROA % only.
GILD' s ROA % Range Over the Past 10 Years
Min: 13.45  Med: 29.12 Max: 42.28
Current: 23.49
13.45
42.28
ROC (Joel Greenblatt) % 561.81
GILD's ROC (Joel Greenblatt) % is ranked higher than
98% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. GILD: 561.81 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GILD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 161.64  Med: 183.96 Max: 595.52
Current: 561.81
161.64
595.52
3-Year Revenue Growth Rate 50.20
GILD's 3-Year Revenue Growth Rate is ranked higher than
86% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. GILD: 50.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GILD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 41.7 Max: 162.8
Current: 50.2
0
162.8
3-Year EBITDA Growth Rate 70.30
GILD's 3-Year EBITDA Growth Rate is ranked higher than
94% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. GILD: 70.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
GILD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -29.8  Med: 38.05 Max: 116.7
Current: 70.3
-29.8
116.7
3-Year EPS without NRI Growth Rate 76.40
GILD's 3-Year EPS without NRI Growth Rate is ranked higher than
95% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. GILD: 76.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
GILD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -19.7  Med: 30.35 Max: 143.5
Current: 76.4
-19.7
143.5
GuruFocus has detected 1 Warning Sign with Gilead Sciences Inc $GILD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GILD's 30-Y Financials

Financials (Next Earnings Date: 2017-08-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

GILD Guru Trades in Q2 2016

John Burbank 730,472 sh (New)
Zeke Ashton 21,500 sh (New)
Steven Cohen 659,100 sh (+94057.14%)
Jeremy Grantham 423,100 sh (+333.50%)
First Eagle Investment 15,500 sh (+68.48%)
Ray Dalio 374,672 sh (+49.98%)
Jim Simons 1,079,348 sh (+49.09%)
David Carlson 730,000 sh (+28.07%)
Lee Ainslie 7,020 sh (+24.69%)
John Rogers 1,443,305 sh (+6.09%)
Joel Greenblatt 1,016,142 sh (+5.01%)
T Rowe Price Equity Income Fund 1,375,000 sh (+1.58%)
Murray Stahl 10,050 sh (+0.50%)
John Buckingham 63,649 sh (+0.26%)
Jeff Auxier 2,982 sh (unchged)
Ronald Muhlenkamp 3,200 sh (unchged)
Julian Robertson 38,511 sh (unchged)
Westport Asset Management 95,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 327,100 sh (unchged)
Leon Cooperman Sold Out
George Soros Sold Out
Ronald Muhlenkamp 217,000 sh (-0.45%)
David Dreman 22,546 sh (-2.86%)
Pioneer Investments 3,465,144 sh (-6.37%)
NWQ Managers 108,300 sh (-6.64%)
Ken Fisher 446,493 sh (-8.32%)
Mario Gabelli 35,819 sh (-11.97%)
Jerome Dodson 265,000 sh (-14.52%)
Dodge & Cox 3,750 sh (-50.79%)
Paul Tudor Jones 13,751 sh (-66.74%)
RS Investment Management 29,512 sh (-80.47%)
» More
Q3 2016

GILD Guru Trades in Q3 2016

First Eagle Investment 49,700 sh (+220.65%)
Jeremy Grantham 1,165,716 sh (+175.52%)
Jim Simons 1,947,048 sh (+80.39%)
Jeff Auxier 4,782 sh (+60.36%)
Jerome Dodson 350,000 sh (+32.08%)
Zeke Ashton 25,000 sh (+16.28%)
Murray Stahl 11,550 sh (+14.93%)
Lee Ainslie 7,880 sh (+12.25%)
John Rogers 1,532,528 sh (+6.18%)
T Rowe Price Equity Income Fund 1,425,000 sh (+3.64%)
Eaton Vance Worldwide Health Sciences Fund 635,263 sh (+94.21%)
David Carlson 730,000 sh (unchged)
First Eagle Investment 300 sh (unchged)
Ronald Muhlenkamp 7,500 sh (unchged)
Julian Robertson 38,511 sh (unchged)
John Burbank 5,000,000 sh (unchged)
Dodge & Cox 3,750 sh (unchged)
Ken Fisher 444,529 sh (-0.44%)
John Buckingham 62,994 sh (-1.03%)
Ronald Muhlenkamp 214,495 sh (-1.15%)
David Dreman 21,855 sh (-3.06%)
Pioneer Investments 3,293,651 sh (-4.95%)
Joel Greenblatt 923,534 sh (-9.11%)
Ray Dalio 315,272 sh (-15.85%)
NWQ Managers 81,896 sh (-24.38%)
Mario Gabelli 12,414 sh (-65.34%)
Steven Cohen 141,000 sh (-78.61%)
Paul Tudor Jones 2,800 sh (-79.64%)
John Burbank 3,224 sh (-99.56%)
» More
Q4 2016

GILD Guru Trades in Q4 2016

Tom Gayner 14,000 sh (New)
Paul Tudor Jones 11,401 sh (+307.18%)
Jim Simons 5,274,948 sh (+170.92%)
Jerome Dodson 490,000 sh (+40.00%)
Jeff Auxier 5,477 sh (+14.53%)
Murray Stahl 13,000 sh (+12.55%)
Joel Greenblatt 1,025,203 sh (+11.01%)
Lee Ainslie 8,520 sh (+8.12%)
John Rogers 1,584,199 sh (+3.37%)
Ken Fisher 455,496 sh (+2.47%)
T Rowe Price Equity Income Fund 1,425,000 sh (unchged)
David Carlson 730,000 sh (unchged)
First Eagle Investment 49,700 sh (unchged)
First Eagle Investment 300 sh (unchged)
Ronald Muhlenkamp 14,800 sh (unchged)
Mario Gabelli 12,414 sh (unchged)
Julian Robertson 38,511 sh (unchged)
John Burbank Sold Out
Steven Cohen Sold Out
Ronald Muhlenkamp 212,995 sh (-0.70%)
David Dreman 20,724 sh (-5.18%)
John Buckingham 59,446 sh (-5.63%)
Dodge & Cox 3,250 sh (-13.33%)
Zeke Ashton 21,000 sh (-16.00%)
Pioneer Investments 2,722,308 sh (-17.35%)
Jeremy Grantham 874,684 sh (-24.97%)
NWQ Managers 61,056 sh (-25.45%)
Ray Dalio 80,272 sh (-74.54%)
Eaton Vance Worldwide Health Sciences Fund 550,067 sh (-13.41%)
» More
Q1 2017

GILD Guru Trades in Q1 2017

John Hussman 50,000 sh (New)
Charles Brandes 108,756 sh (New)
Steven Cohen 566,100 sh (New)
Tom Gayner 27,000 sh (+92.86%)
Paul Tudor Jones 20,709 sh (+81.64%)
T Rowe Price Equity Income Fund 2,560,000 sh (+79.65%)
Jim Simons 7,707,248 sh (+46.11%)
Jerome Dodson 601,000 sh (+22.65%)
Jeff Auxier 6,677 sh (+21.91%)
First Eagle Investment 59,700 sh (+20.12%)
Joel Greenblatt 1,212,036 sh (+18.22%)
John Rogers 1,800,201 sh (+13.63%)
Mario Gabelli 14,080 sh (+13.42%)
Lee Ainslie 9,460 sh (+11.03%)
John Buckingham 63,635 sh (+7.05%)
Ronald Muhlenkamp 225,725 sh (+5.98%)
Murray Stahl 13,600 sh (+4.62%)
First Eagle Investment 300 sh (unchged)
Dodge & Cox 3,250 sh (unchged)
Julian Robertson 38,511 sh (unchged)
Steven Cohen 28,700 sh (unchged)
Ronald Muhlenkamp 28,600 sh (unchged)
David Carlson 730,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 550,067 sh (unchged)
Ray Dalio Sold Out
Zeke Ashton Sold Out
Ken Fisher 451,634 sh (-0.85%)
David Dreman 20,174 sh (-2.65%)
NWQ Managers 52,811 sh (-13.50%)
Pioneer Investments 1,898,063 sh (-30.28%)
Jeremy Grantham 37,400 sh (-95.72%)
» More
» Details

Insider Trades

Latest Guru Trades with GILD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:CELG, OTCPK:NONOF, OTCPK:SHPGF, NAS:BIIB, NAS:AMGN, NAS:REGN, OTCPK:CSLLY, NAS:VRTX, OTCPK:ALIOY, NAS:INCY, NAS:ALXN, OTCPK:GIKLY, OTCPK:UCBJY, NAS:BMRN, OTCPK:NVZMF, OTCPK:GMXAY, NAS:SGEN, NAS:JAZZ, NAS:ALKS, NAS:TSRO » details
Traded in other countries:GILD34.Brazil, GILD.Chile, GIS.Germany, GILD.Mexico, GILD.Switzerland,
Headquarter Location:USA
Gilead Sciences Inc is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of the recently approved combination regimen Harvoni.

Guru Investment Theses on Gilead Sciences Inc

Jerome Dodson Comments on Gilead - Jan 25, 2017

Our other laggard was Gilead (NASDAQ:GILD), a biotechnology firm that makes therapies for HIV and Hepatitis C. Gilead sliced 98 basis points off the Fund’s return, as its stock declined 29.2%, from $101.19 to $71.61. The stock dropped due to weakness in the Hepatitis C business, as pricing came under pressure due to increased competition, and the patient population fell because Gilead’s drugs cure patients of this damaging disease. The stock is on the bargain table, and the company has a strong balance sheet and a proven track record of innovation, so we increased our position throughout the year.



From the Parnassus Fund fourth quarter 2016 commentary.



Check out Jerome Dodson latest stock trades

Jerome Dodson Comments on Gilead - Jul 26, 2016

Gilead (NASDAQ:GILD), a biotechnology firm that makes therapies for HIV and hepatitis C, sliced 21 basis points off the Fund’s return, as its stock declined 9.2% from $91.86 to $83.42. The company’s underperformance was driven by weakness in its hepatitis C business, as pricing came under pressure due to increased competition. Given Gilead’s proven track record of innovation and its strong balance sheet, we believe the company has many opportunities, not only to maintain leadership in HIV and hepatitis C, but also to expand its portfolio into new therapeutic areas.


From Jerome Dodson (Trades, Portfolio)'s Parnassus Fund second quarter 2016 commentary.

Check out Jerome Dodson latest stock trades

John Rogers Comments on Gilead Sciences Inc. - Dec 02, 2015

Biotechnology leader Gilead Sciences, Inc. (NASDAQ:GILD) dropped -15.90% on recent concerns over drug pricing. Gilead actually reported quarterly earnings that were better than expected. We continue to hold the shares, based on our belief that the market is overly focused on pricing and underestimating future sales that we think are likely to grow.





From John Rogers (Trades, Portfolio) 3rd quarter commentary on the Ariel Global Fund.

Check out John Rogers latest stock trades

Top Ranked Articles about Gilead Sciences Inc

Stocks That Fell to 3-Year Lows in the Week of May 12 Gilead Sciences, Ford Motor, Taubman Centers and Dillard's have declined to their respective lows
Gilead Sciences Inc. (NASDAQ:GILD), Ford Motor Co. (NYSE:F), Taubman Centers Inc. (NYSE:TCO) and Dillard's Inc. (NYSE:DDS) have declined to their three-year lows. Read more...
Stocks That Fell to 3-Year Lows in the Week of April 14 Gilead Sciences, Target, New York Community Bancorp and Ralph Lauren fell to their three-year lows
Gilead Sciences Inc. (NASDAQ:GILD) declined to $66.51 Read more...
Executive Chairman Slashes Stake in Gilead Sciences Company's market price has fallen an estimated 25% over the previous year
Insider John Martin, the executive chairman of Gilead Sciences (NASDAQ:GILD), sold 73,333 shares on March 3 for $70.38 per share according to a Form 4 filing with the securities and exchange commission Read more...
Gilead Sciences, Fossil Reach 3-Year Low Prices Stocks that have reached historical low prices
Gilead Sciences Inc. (NASDAQ:GILD) reached $66.36 Read more...
Jerome Dodson Comments on Gilead Guru stock highlight
Our other laggard was Gilead (NASDAQ:GILD), a biotechnology firm that makes therapies for HIV and Hepatitis C. Gilead sliced 98 basis points off the Fund’s return, as its stock declined 29.2%, from $101.19 to $71.61. The stock dropped due to weakness in the Hepatitis C business, as pricing came under pressure due to increased competition, and the patient population fell because Gilead’s drugs cure patients of this damaging disease. The stock is on the bargain table, and the company has a strong balance sheet and a proven track record of innovation, so we increased our position throughout the year. Read more...
Jerome Dodson Adds to Gilead Sciences Position Company's price is close to 3-year low
Guru Jerome Dodson (Trades, Portfolio) added 140,000 shares of Gilead Sciences (NASDAQ:GILD) during the fourth quarter. Read more...
Gilead Sciences Must Answer to Investors After a Disappointing 2016 Investors are concerned about the company's lack of a plan for the future
Gilead Sciences Inc. (NASDAQ:GILD) delivered a poor performance last year. The stock lost over 24% in 2016, caused by a drop in sales of products that treat hepatitis C. According to Ben Levinsohn in a Barron's article, the decline was also attributed to the company’s lack of a plan for the future. Read more...
Gilead Sciences’ Miracle Drug Combination The complexity of analyzing drug companies
It was 1986. I was a junior high school student in Soviet Russia. In political information (propaganda) class, the teacher told us that the HIV virus was killing millions of people in the U.S. Though she didn’t say it explicitly, she made it sound like HIV was a just punishment for the U.S.’s flawed economic and political system. When asked if this virus could be cured, she said that because it constantly mutated it was incurable. (And in fact, HIV reproduces 12 million times daily.) Once you get sick, it’s a death sentence, she told us. I still remember the chilling and morbid certainty in her voice. Read more...
Gilead’s Patience Is Wearing Investors' Patience Thin Despite sitting on a cash pile, the company has been slow in the acquisitions space
Gilead’s (NASDAQ:GILD) stock price has been on a never-ending slide since the second half of last year. The stock is now trading at less than 7 times earnings after dropping more than a quarter of its valuation in the last twelve months. But a key question that remains after analyzing Gilead is why the company is sitting on its cash pile without doing anything. Read more...
Gilead Sciences: Cheap Growth or Value Trap? GILD has plunged over 30% since its peak in mid-2015 and now trades for less than 10 times earnings. Are the best days behind the company, or is GILD a bargain?
Gilead Sciences (NASDAQ:GILD), the dominant antiviral and hepatitis drug company, is starting to draw a lot of attention from value oriented investors due to its decline of 23% over the past year. Read more...

Ratios

vs
industry
vs
history
PE Ratio 6.83
GILD's PE Ratio is ranked higher than
92% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 28.38 vs. GILD: 6.83 )
Ranked among companies with meaningful PE Ratio only.
GILD' s PE Ratio Range Over the Past 10 Years
Min: 6.67  Med: 16.4 Max: 45.49
Current: 6.83
6.67
45.49
Forward PE Ratio 7.94
GILD's Forward PE Ratio is ranked higher than
96% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 18.05 vs. GILD: 7.94 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 6.83
GILD's PE Ratio without NRI is ranked higher than
92% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 29.63 vs. GILD: 6.83 )
Ranked among companies with meaningful PE Ratio without NRI only.
GILD' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.67  Med: 16.28 Max: 45.49
Current: 6.83
6.67
45.49
Price-to-Owner-Earnings 5.94
GILD's Price-to-Owner-Earnings is ranked higher than
88% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. GILD: 5.94 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
GILD' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.68  Med: 15.05 Max: 74.51
Current: 5.94
5.68
74.51
PB Ratio 4.17
GILD's PB Ratio is ranked lower than
60% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. GILD: 4.17 )
Ranked among companies with meaningful PB Ratio only.
GILD' s PB Ratio Range Over the Past 10 Years
Min: 4.15  Med: 8.26 Max: 18.71
Current: 4.17
4.15
18.71
PS Ratio 2.97
GILD's PS Ratio is ranked higher than
80% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. GILD: 2.97 )
Ranked among companies with meaningful PS Ratio only.
GILD' s PS Ratio Range Over the Past 10 Years
Min: 2.95  Med: 6.59 Max: 12.5
Current: 2.97
2.95
12.5
Price-to-Free-Cash-Flow 5.84
GILD's Price-to-Free-Cash-Flow is ranked higher than
89% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. GILD: 5.84 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GILD' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.66  Med: 16.6 Max: 49.26
Current: 5.84
5.66
49.26
Price-to-Operating-Cash-Flow 5.59
GILD's Price-to-Operating-Cash-Flow is ranked higher than
90% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. GILD: 5.59 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GILD' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.41  Med: 15.69 Max: 45.09
Current: 5.59
5.41
45.09
EV-to-EBIT 5.66
GILD's EV-to-EBIT is ranked higher than
82% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. GILD: 5.66 )
Ranked among companies with meaningful EV-to-EBIT only.
GILD' s EV-to-EBIT Range Over the Past 10 Years
Min: -154.2  Med: 12 Max: 209.2
Current: 5.66
-154.2
209.2
EV-to-EBITDA 5.30
GILD's EV-to-EBITDA is ranked higher than
82% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. GILD: 5.30 )
Ranked among companies with meaningful EV-to-EBITDA only.
GILD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -189.9  Med: 11.3 Max: 168
Current: 5.3
-189.9
168
PEG Ratio 0.13
GILD's PEG Ratio is ranked higher than
98% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 2.13 vs. GILD: 0.13 )
Ranked among companies with meaningful PEG Ratio only.
GILD' s PEG Ratio Range Over the Past 10 Years
Min: 0.11  Med: 0.48 Max: 3.81
Current: 0.13
0.11
3.81
Shiller PE Ratio 15.08
GILD's Shiller PE Ratio is ranked higher than
89% of the 53 Companies
in the Global Biotechnology industry.

( Industry Median: 53.05 vs. GILD: 15.08 )
Ranked among companies with meaningful Shiller PE Ratio only.
GILD' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.97  Med: 54.63 Max: 2078
Current: 15.08
14.97
2078
Current Ratio 2.59
GILD's Current Ratio is ranked lower than
71% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. GILD: 2.59 )
Ranked among companies with meaningful Current Ratio only.
GILD' s Current Ratio Range Over the Past 10 Years
Min: 1.09  Med: 7.06 Max: 57.67
Current: 2.59
1.09
57.67
Quick Ratio 2.41
GILD's Quick Ratio is ranked lower than
70% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. GILD: 2.41 )
Ranked among companies with meaningful Quick Ratio only.
GILD' s Quick Ratio Range Over the Past 10 Years
Min: 0.83  Med: 6.59 Max: 57.67
Current: 2.41
0.83
57.67
Days Inventory 157.84
GILD's Days Inventory is ranked lower than
59% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. GILD: 157.84 )
Ranked among companies with meaningful Days Inventory only.
GILD' s Days Inventory Range Over the Past 10 Years
Min: 148.53  Med: 221.48 Max: 276.35
Current: 157.84
148.53
276.35
Days Sales Outstanding 50.60
GILD's Days Sales Outstanding is ranked higher than
55% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. GILD: 50.60 )
Ranked among companies with meaningful Days Sales Outstanding only.
GILD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.6  Med: 69.31 Max: 84.93
Current: 50.6
50.6
84.93
Days Payable 85.60
GILD's Days Payable is ranked higher than
67% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. GILD: 85.60 )
Ranked among companies with meaningful Days Payable only.
GILD' s Days Payable Range Over the Past 10 Years
Min: 85.6  Med: 158.55 Max: 207.21
Current: 85.6
85.6
207.21

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.98
GILD's Dividend Yield % is ranked higher than
82% of the 212 Companies
in the Global Biotechnology industry.

( Industry Median: 1.05 vs. GILD: 2.98 )
Ranked among companies with meaningful Dividend Yield % only.
GILD' s Dividend Yield % Range Over the Past 10 Years
Min: 0.36  Med: 2.03 Max: 3
Current: 2.98
0.36
3
Dividend Payout Ratio 0.20
GILD's Dividend Payout Ratio is ranked higher than
87% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 0.31 vs. GILD: 0.20 )
Ranked among companies with meaningful Dividend Payout Ratio only.
GILD' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.11  Med: 0.15 Max: 0.2
Current: 0.2
0.11
0.2
Forward Dividend Yield % 3.23
GILD's Forward Dividend Yield % is ranked higher than
86% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 1.05 vs. GILD: 3.23 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.00
GILD's 5-Year Yield-on-Cost % is ranked higher than
71% of the 265 Companies
in the Global Biotechnology industry.

( Industry Median: 1.54 vs. GILD: 3.00 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
GILD' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.36  Med: 2.03 Max: 3
Current: 3
0.36
3
3-Year Average Share Buyback Ratio 5.10
GILD's 3-Year Average Share Buyback Ratio is ranked higher than
99% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. GILD: 5.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GILD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.6  Med: -3.9 Max: 6.1
Current: 5.1
-25.6
6.1

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 8.13
GILD's Price-to-Tangible-Book is ranked lower than
79% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. GILD: 8.13 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GILD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.51  Med: 8.57 Max: 214.73
Current: 8.13
1.51
214.73
Price-to-Intrinsic-Value-Projected-FCF 0.53
GILD's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
93% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. GILD: 0.53 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
GILD' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.52  Med: 2.12 Max: 20.83
Current: 0.53
0.52
20.83
Price-to-Median-PS-Value 0.45
GILD's Price-to-Median-PS-Value is ranked higher than
81% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. GILD: 0.45 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GILD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.44  Med: 1.83 Max: 30
Current: 0.45
0.44
30
Price-to-Peter-Lynch-Fair-Value 0.27
GILD's Price-to-Peter-Lynch-Fair-Value is ranked higher than
98% of the 66 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. GILD: 0.27 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
GILD' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.27  Med: 0.93 Max: 9.13
Current: 0.27
0.27
9.13
Price-to-Graham-Number 1.57
GILD's Price-to-Graham-Number is ranked higher than
66% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 2.64 vs. GILD: 1.57 )
Ranked among companies with meaningful Price-to-Graham-Number only.
GILD' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.56  Med: 3.46 Max: 15.78
Current: 1.57
1.56
15.78
Earnings Yield (Greenblatt) % 17.72
GILD's Earnings Yield (Greenblatt) % is ranked higher than
94% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. GILD: 17.72 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GILD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.5  Med: 7.7 Max: 17.83
Current: 17.72
0.5
17.83
Forward Rate of Return (Yacktman) % 70.99
GILD's Forward Rate of Return (Yacktman) % is ranked higher than
98% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 16.45 vs. GILD: 70.99 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
GILD' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.2  Med: 6.4 Max: 71
Current: 70.99
1.2
71

More Statistics

Revenue (TTM) (Mil) $29,101
EPS (TTM) $ 9.47
Beta0.99
Short Percentage of Float0.81%
52-Week Range $63.88 - 88.85
Shares Outstanding (Mil)1,306.73

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 24,308 22,319 20,821
EPS ($) 7.99 7.37 6.96
EPS without NRI ($) 7.99 7.37 6.96
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-9.75%
Dividends per Share ($) 1.94 2.04 1.88
» More Articles for GILD

Headlines

Articles On GuruFocus.com
Stocks That Fell to 3-Year Lows in the Week of May 12 May 14 2017 
Charles Brandes Invests in Health Care in 1st Quarter May 11 2017 
BetterInvesting Top 100, Reflecting the Portfolios of Main Street Investors, Rises in April and Gain May 04 2017 
Jerome Dodson Keeps Buying McKesson, Axalta, Pentair Apr 25 2017 
The Better Big Pharma Stock: AbbVie or Gilead? Apr 18 2017 
FDA Rejects Eli Lilly, Incyte's Commercialization Application Apr 18 2017 
Stocks That Fell to 3-Year Lows in the Week of April 14 Apr 16 2017 
7 Stocks With Rising Revenue and EPS Apr 11 2017 
A Socially Conscious Guru Apr 07 2017 
Special Investors Release: Covered call stock options reports for Comcast, Salesforce, Gilead Scienc Apr 06 2017 

More From Other Websites
Amgen's Woes: It Could Always Be Worse! May 22 2017
Cramer's lightning round: I've got a message for the struggling Gilead Sciences May 19 2017
5 Reasons Big Biotech Could Gain 25%-30% May 19 2017
Why Stay Bullish On Gilead May 19 2017
Revisiting Bristol-Myers Squibb’s Virology in 1Q17 May 19 2017
Top 5 Biotech Stocks for 2017 May 19 2017
A Doomed Trump Presidency Would Be a Terrifying Development for Pharmaceutical Stocks May 18 2017
3 Dividend Stocks You Haven't Thought Of May 17 2017
3 Best Dividend Stocks in Biotech May 16 2017
Gilead's last chronic HIV drug — and what it plans to do now May 15 2017
Blog Coverage: Ardelyx Reports Successful Trial Results for Treatment of Patients with Irritable... May 15 2017
Better Buy: Gilead Sciences, Inc. vs. Amgen Inc. May 14 2017
Johnson & Johnson Analyst Day May 12 2017
3 Top Biotech Stocks For May May 11 2017
Major Biotech Short Interest Remains Mixed May 10 2017
Why Gilead Sciences Stock Lagged Behind Other Biotechs in April May 10 2017
Here's Why Diplomat Pharmacy Inc. Is Rising Today May 09 2017
I Still Can't Believe Gilead Sciences, Inc. Spent $14.8 Billion on Shareholder Rewards May 09 2017
3 Stocks That Generate Tons of Cash May 09 2017
Gilead Sciences, Inc. breached its 50 day moving average in a Bearish Manner : GILD-US : May 8, 2017 May 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat